Construction of physiologically-based pharmacokinetic (PBPK) model of rifampicin to predict metabolic enzyme induction- and hepatic uptake transporter inhibition-mediated drug-drug interaction (DDI)

Ryuta Asaumi

Presentation information

Oral Presentation

2．Drug Interaction

Thu. Nov 12, 2015 10:40 AM - 11:30 AM Room E (2Ｆ Zuiun)

Chair:Masato Chiba (Pharmacokinetics Research Laboratories, Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., LTD.), Masahiro Iwaki (Division of Biopharmaceutics, Department of Pharmacy, Faculty of Pharmacy, Kinki University)

[O2-3] Construction of physiologically-based pharmacokinetic (PBPK) model of rifampicin to predict metabolic enzyme induction- and hepatic uptake transporter inhibition-mediated drug-drug interaction (DDI)

^○Ryuta Asaumi , Kenichi Nunoya ¹, Haruo Imawaka ¹, Yuichi Sugiyama ² (1.Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co.,Ltd., 2.Sugiyama Laboratory, RIKEN Innovation Center, RIKEN)

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.